News and Announcements

Keep up with the latest headlines

Recent News

Stay connected, stay ahead. Know everything that matters, as it happens. From the very latest industry news, reports, papers, and studies. Would you like to see your news here? Email the admin and we will get it linked.

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening
June 23, 2021

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening

Sanford M. Simon and his group tested over 5,000 compounds, either already approved for other clinical uses or in clinical trials, to see whether any of the compounds could be repurposed to treat fibrolamellar. The team used PDX models to uncover a few classes of therapeutics that eliminate fibrolamellar tumor cells grown in mice.

Read MORE
2021 VIRTUAL Functional Precision Medicine in Blood Cancer
June 16, 2021

2021 VIRTUAL Functional Precision Medicine in Blood Cancer

The 2021 Functional Precision Medicine in Blood Cancer Symposium which took place virtually on March 25-26th, 2021 was very interesting and well attended. If you were not able to make it please take a moment to watch the recording by clicking on the "Learn More" button below.

Read MORE
SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer
April 13, 2021

SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer

SEATTLE, April 13, 2021 -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS® Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS® Test (abstract number 534) at the American Association for Cancer Research annual meeting, taking place virtually from April 10-15, 2021.

Read MORE
2021 Functional Precision Medicine in Blood Cancer Symposium
March 8, 2021

2021 Functional Precision Medicine in Blood Cancer Symposium

We cordially invite you to the 2021 Functional Precision Medicine in Blood Cancer Symposium that will be hosted in the context of a European Functional Precision Medicine Initiative in cooperation with the EHA-SWG Functional Precision Hematology, and the Society for Functional Precision Medicine. The symposium will take place March 25-26th, 2021 – virtual - and will bring together global experts on high-throughput drug screening, precision medicine and blood cancer. You’ll see familiar faces from the SfPM and more!


Please click the button below to register. To preview the schedule, please click here.

Read MORE
Two postdoc positions in computational cancer biology at NTNU
January 28, 2021

Two postdoc positions in computational cancer biology at NTNU

Are you a computational biologist or bioinformatician eager to apply your skills and ingenuity to tackle cancer? We open two postdoc researcher positions at NTNU as part of our ERA PerMed project ONCOLOGICS. The two appointed postdocs will work in close collaboration with each other and with a large research team from leading European research organizations.

Read MORE
Plenary Sesion - A podcast on medicine, oncology, & health policy
October 22, 2020

Plenary Sesion - A podcast on medicine, oncology, & health policy

Dr Anthony Letai sits down with Dr Vinay Prasad for a an episode of Plenary Session where Dr Letai speaks about precision oncology, the Match trial and NGS in cancer. Be sure to check it out!

Read MORE
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
August 17, 2020

Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional predictive biomarker that measures net changes in mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat resistance and avoid relapse.

Read MORE
Tumor Organoids for Functional Precision Oncology
July 15, 2020

Tumor Organoids for Functional Precision Oncology

Researchers are using patient-derived tumor organoids to match patients with optimal treatments - When most people think of precision cancer medicine, they think of genomics, with researchers trying to decipher complex gene interactions for the clinical benefit of patients. But according to Dr. Christopher Kemp, a cancer biologist at the Fred Hutchinson Cancer Research Center, that is a narrow view: “[Genomics] is important, but it’s not the whole puzzle by any stretch.”

Read MORE
Predicting response to therapy with BH3 profiling - Authored by SFPM President Anthony Letai, PhD
June 29, 2020

Predicting response to therapy with BH3 profiling - Authored by SFPM President Anthony Letai, PhD

Anthony Letai, PhD gives an overview of how BH3 profiling can be used to predict response to therapy. “There is an enormous amount of actionable information that can be obtained from taking the actual cancer cell you’re interested in and subjecting it to a relevant perturbation, that is, exposing it to the actual drugs,” he said. “We nearly completely overlook this in today’s precision medicine approaches, and I think there is enormous unrealized potential in this general approach.”

Read MORE
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors - Authored by Letai Lab member Patrick Bhola, PhD
June 29, 2020

High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors - Authored by Letai Lab member Patrick Bhola, PhD

“Cancer cells that are cultured for extended periods of time can undergo a variety of changes and may not be representative of the tumor cells that are actually in a mouse or human,” says study first author Patrick Bhola, PhD, of Dana-Farber. “The challenge has been to create a drug-screening technique that shrinks the gap between tumor cells in the body and the cells we do the screening on. The technique we’ve developed helps to accomplish that.” Read Dana Farber’s press release about HT-DBP technology for more information.

Read MORE